potent, oral heme-displacing IDO1 inhibitor

low predicted human dose (<10 mg QD)

from ALIS mass-based binding screen + SBDD

ACS Med. Chem. Lett., Jul. 15, 2020

Merck & Co., Boston, MA

Structure of compound 2

“compound 2” is a heme-displacing IDO1 inhibitor with a similar binding mode to BMS-986205 with a low projected human dose. A bis-amide hit was generated from a mass-spectrometry based binding…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: